AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Inclusion Criteria: * Subjects must have a histologically confirmed metastatic RCC with a clear cell component * Low or intermediate risk according to the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk classification. * Measurable disease with at least one unidimensionally measurable lesion per RECIST guidelines with modifications * Adequate organ and hematological function as evidenced by laboratory studies conducted at Screening. * ECOG of 0 or 1 Exclusion Criteria: Disease Related * Known history of central nervous system metastases. * Previous treatment (excluding surgery and palliative radiotherapy) for advanced or metastatic renal cell carcinoma * Focal radiation therapy for palliation of pain from bony metastases within 14 days of randomization. Medications * Currently or previously treated with inhibitors of VEGF. * Currently or previously treated with inhibitors of angiopoietin or Tie2. * Currently or previously treated with bevacizumab. General Medical * Diagnosis of acute pancreatitis. * Myocardial infarction, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, congestive heart failure, grade 2 or greater peripheral vascular disease, arrhythmias not controlled by outpatient medication, or unstable angina within 1 year prior to randomization * Major surgery within 30 days before randomization or still recovering from prior surgery * Uncontrolled hypertension as defined as diastolic \> 90 mmHg OR systolic \>150 mmHg. Anti-hypertensive medications are permitted. Other * Other investigational procedures are excluded * Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)